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Rationale: Diaphragm weakness impairs quality-of-life, exercise capacity, and survival in patients with 3 
chronic heart failure (CHF) and reduced left ventricular ejection fraction. However, the underlying 4 
cellular mechanisms responsible in humans remain poorly resolved.  5 
Objectives: We prospectively evaluated clinical, functional (in vivo/in vitro), 6 
histological/ultrastructural and molecular alterations of the diaphragm from CHF patients receiving a 7 
left ventricular assist device compared to patients without CHF undergoing elective coronary bypass 8 
grafting (control) in the observational LIpsia DiaPhrAgm and MUScle Heart Failure Trial (LIPAMUS-9 
HF). 10 
Methods and Results: Participants (Controls=21, CHF=18) underwent cardiopulmonary exercise and 11 
spirometry/respiratory muscle testing alongside diaphragm and cardiac imaging. Diaphragm biopsies 12 
were phenotyped for mitochondrial respiration, muscle fiber function, histology/ultrastructure, and 13 
protein expression. 14 
In vivo respiratory muscle function and diaphragm thickness were reduced in CHF by 38% and 23%. 15 
Diaphragm biopsies revealed a fiber-type shift and severe fiber atrophy in CHF alongside elevated 16 
proteasome-dependent proteolysis (i.e., MuRF1 expression, ubiquitination, ubiquitin proteasome 17 
activity) and myofibrillar protein oxidation, which corresponded to upregulated NADPH oxidase 18 
(Nox2/Nox4) signaling. Mitochondria demonstrated severe intrinsic functional and ultrastructural 19 
abnormalities in CHF characterized by accumulation of small mitochondria and inhibited 20 
autophagy/mitophagy. Single muscle fiber contractile function revealed reduced Ca2+ sensitivity in CHF 21 
and there was evidence of ryanodine receptor 1 (RyR1) dysfunction indicating Ca2+ leak from the 22 
sarcoplasmatic reticulum. Mitochondrial and Ca2+ measures corresponded to upregulated Nox4 isoform 23 
NADPH oxidase expression. Molecular markers correlated to whole-body exercise intolerance and 24 
diaphragm dysfunction/wasting. 25 
Conclusions: CHF patients demonstrate an obvious diaphragm myopathy independent of disuse or other 26 
confounding factors such as ageing, obesity, or hypertension. Diaphragm weakness in CHF was 27 
associated with intracellular abnormalities characterized by fiber atrophy, oxidative stress, 28 
mitochondrial dysfunction, impaired Ca2+ homeostasis, elevated proteasome dependent proteolysis, but 29 
inhibited autophagy/mitophagy, which we speculate offers a novel therapeutic molecular target 30 
regulated by a Nox-MuRF1/ubiquitin proteasome-mitochondria-RyR1/Ca2+ signaling axis.  31 
 32 
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02663115 33 
 34 
Keywords: diaphragm; humans; heart failure; MuRF1, NADPH 35 
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Non-standard Abbreviations and Acronyms 1 
 2 
ATP – adenosine triphosphate 3 
CABG – coronary artery bypass grafting 4 
CHF – chronic heart failure 5 
ETC – electron transfer chain  6 
FEV1 – forced expiratory volume in 1 second 7 
ROS – reactive oxygen species 8 
SR – sarcoplasmic reticulum 9 
UPS – ubiquitin-proteasome system 10 
VC – vital capacity 11 
VE/VCO2 – ratio ventilation to carbon dioxide output 12 
VO2peak – maximal oxygen uptake 13 





The diaphragm is the main respiratory muscle responsible for normal ventilatory behaviors.1 Diaphragm 3 
weakness is common in patients with chronic heart failure (CHF) 2 and is closely associated with 4 
symptoms and mortality. 3, 4 Yet, the underlying mechanisms in humans remain only partially resolved 5 
5-8 and most of our knowledge is derived from animal models. 9-11 Of the few human studies performed, 6 
most were underpowered, or lacked modern molecular biology approaches 5-8, thus limiting our 7 
mechanistic understanding and potential treatment options for the current patient.  8 
Both acute 9 and chronic heart failure 11 cause diaphragm weakness in CHF mouse models, which is 9 
characterized by both fiber contractile dysfunction and fiber atrophy. 11-14 Reactive oxygen species 10 
(ROS) play a causal role to induce diaphragm weakness 15, 16 since antioxidant interventions such as 11 
exercise training 11, pharmacological aids 17, or genetic deletion 18 can prevent diaphragm weakness by 12 
reducing posttranslational oxidative modifications of contractile proteins and suppressing protein 13 
degradation via the ubiquitin-proteasome system 19 in a MuRF1 dependent manner. 20 In end-stage CHF 14 
patients, the diaphragm shows ultra-structural and myofibrillar alterations that implicate metabolic and 15 
contractile abnormalities 6, 8, which are related to NADPH signaling. 5 Animal models have identified 16 
NADPH oxidase 21 and mitochondria 16, 22 as major sources of ROS, but their role in the human 17 
diaphragm remains poorly defined. In addition, the level of structural and molecular alterations in the 18 
diaphragm has never been extensively linked to clinical presentation. 19 
We hypothesized that CHF patients would have a distinctive diaphragm myopathy, which would closely 20 
correlate to clinical observations. The present study, therefore, evaluated clinical, histological and 21 
molecular evidence from diaphragm biopsies in CHF patients scheduled for left ventricular assist device 22 





The data that support the findings of this study are available from the corresponding author upon 3 
reasonable request. Patients with severe CHF and reduced left ventricular ejection fraction (LV-EF) 4 
scheduled for left ventricular assist device implantation and patients with coronary artery disease 5 
(control) undergoing elective coronary artery bypass grafting without CHF were eligible for this study. 6 
All patients gave written informed consent. The trial was approved by the local ethics committee, 7 
complied with the Declaration of Helsinki, and is registered at www.clinicaltrials.gov (Unique 8 
Identifier: NCT02663115).  9 
Categorical variables are given as numbers and percentage compared between groups by the chi-squared 10 
test or Fisher exact test as appropriate. Continuous variables are shown as mean and 95%-confidence 11 
interval irrespective of its distribution assessed by the Shapiro-Wilk-Test. Groups were compared using 12 
the Students t-test or Mann-Whitney-U-Test according to normal vs non-normal distribution. Due to 13 
limited biopsy size, not all parameters were determined in all biopsies, exact numbers and all values 14 
depicted in the Figures are given in Online Table I. For all the representative images in the manuscript, 15 
demonstrative examples reflecting the group mean trend were selected. Correlation analyses were 16 
performed using Pearson correlation to evaluate the association of both potential biological pathways 17 
predominantly known from animal studies and molecular measures with three defined clinical 18 
parameters (diaphragm thickness, VO2peak, VE/VCO2). A two-sided p-value <0.05 was considered 19 
significant. 20 
For detailed methodological information, please refer to the Online Supplement and the Major 21 
Resources Table.  22 





Baseline characteristics 3 
Between January 2016 and December 2017, 18 CHF patients and 21 controls were included. Baseline 4 
characteristics are shown in Table 1. Compared to controls, CHF were slightly younger, had worse renal 5 
function, a lower body mass index, and lower rates of coronary artery disease, but had a higher incidence 6 
of atrial fibrillation and previous cardiac surgery (all p<0.05). One third of CHF had ischemic and two 7 
thirds had dilated cardiomyopathy. With regard to whole body exercise capacity, CHF exhibited a 35% 8 
lower VO2peak and a significantly higher VE/VCO2 slope than controls, whereas the respiratory exchange 9 
ratio was comparable indicating physical exhaustion in both groups (Online Table II). Catheterization 10 
data of CHF are provided in Online Table III. 11 
 12 








Age [years] 62 (60; 65) 57 (53; 61) 0.014* 
Male Gender, n (%) 17 (81.0) 17 (94.4) 0.349† 
Caucasian ethnicity, n (%) 21 (100) 18 (100) n.a. 












Heart rate [min-1] 76 (69; 82) 82 (75; 89) 0.180‡ 
New York Heart Association class   3.4E-4§ 
I 2 (9.5) 0 (0)  
II 14 (66.7) 2 (11.1)  
III 5 (23.8) 10 (55.6)  
IV 0 (0) 6 (33.3)  







Coronary artery disease, n (%) 21 (100) 10 (55.6) 7.1E-4† 
Previous Myocardial Infarction, n (%) 1 (4.8) 5 (27.8) 0.077† 
Previous percutaneous coronary intervention, n (%) 5 (23.8) 8 (44.4) 0.173§ 
Previous cardiac surgery, n (%) 0 (0) 4 (22.2) 0.037† 
Atrial fibrillation/flutter, n (%) 2 (9.5) 11 (61.1) 6.6E-4§ 
Arterial hypertension, n (%) 20 (95.2) 17 (94.4) 1.000† 
Diabetes mellitus, n (%) 10 (47.6) 10 (55.6) 0.521$ 
Previous stroke, n (%) 0 (0) 1 (5.6) 0.462† 
Peripheral artery disease, n (%) 1 (4.8) 2 (11.1) 0.586† 
Chronic kidney disease, stage ≥3b, n (%) 0 (0) 9 (50) 2.3E-4† 




Heart failure features 
Ischemic cardiomyopathy, n (%) n.a. 6 (33.3) n.a. 
Dilated cardiomyopathy, n (%) n.a. 12 (66.7)  









Left ventricular-ejection fraction [%] 61 (58; 64) 19 (17; 22) 8.6E-23‡ 
Left ventricular enddiastolic diameter [mm] 51 (49; 53) 73 (69; 77) 5.2E-11‡ 
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Left atrial volume index [ml/m²) 34 (28; 41) 63 (54; 72) 6.2E-6* 
Right ventricular enddiastolic parameter [mm] 29 (27; 32) 38 (34; 41) 1.4E-4‡ 
Right atrial area [mm²] 13 (12; 15) 23 (19; 28) 2.8E-4‡ 
Tricuspid annular plane excursion [mm] 23 (20; 25) 14 (12; 15) 2.6E-7‡ 
Diameter inferior vena cava [mm] 14 (13; 16) 19 (16; 22) 1.1E-3‡ 
Lung function 
VC [l] 3.9 (3.4; 4.3) 3.2 (2.9; 3.4) 8.0E-3‡ 
FEV1 [l] 3.1 (2.8; 3.5) 2.6 (2.3; 2.9) 0.022‡ 
FEV1/VC [%] 81 (78; 85) 79 (75; 83) 0.250‡ 







Transfer coefficient [%] 99 (92; 106) 80 (73; 87) 3.8E-4‡ 
Treatments at inclusion 
Beta-blocker, n (%) 17 (81.0) 17 (94.4) 0.349† 
ACE-inhibitor, n (%) 8 (38.1) 7 (38.9) 0.959§ 
Angiotensin receptor blocker, n (%) 8 (38.1) 0 (0) 4.0E-3† 
Neprylisin inhibitor/angiotensin receptor blocker, n 
(%) 
0 (0) 6 (33.3) 5.7E-3† 
Mineral receptor antagonist, n (%) 1 (4.8) 16 (88.9) 1.3E-7§ 
Digitoxin, n (%) 0 (0) 4 (22.2) 0.037† 
Diuretics, n (%) 10 (47.6) 16 (88.9) 6.4E-3§ 
Intravenous Phosphodiesterase inhibitor, n (%) 0 (0) 15 (83.3) 9.7E-8§ 
Implantable cardioverter defibrillator, n (%) 0 (0) 16 (88.9) 1.8E-8§ 
Cardiac resynchronization therapy, n (%) 0 (0) 4 (22.2) 0.037† 
 1 
Values are expressed as mean with 95%-confidence interval or numbers and percentages. STS indicates 2 
Society of Thoracic Surgeons score; CABG, coronary artery bypass grafting; VC, vital capacity; FEV1, 3 
forced expiratory volume in 1 second; ACE, angiotensin converting enzyme. 4 
All p-values are two-sided and were not corrected for multiple testing. Continuous variables were tested 5 
for normal distribution applying the Shapiro-Wilk-test. 6 
* Mann-Whitney-U-Test 7 
† Fisher exact test 8 
‡ unpaired Students t-test 9 
§ chi-squared test 10 
 11 
In vivo respiratory function  12 
Pimax and Pemax were significantly reduced by 38% and 25% in CHF compared to controls (Figure 1 A). 13 
P0.1 was not significantly different between groups; however, P0.1/Pimax ratio was higher in CHF 14 
indicating increased ventilatory drive (Figure 1 B, Online Table II). Diaphragm wasting was obvious in 15 
CHF, with mean diaphragm thickness 23% lower compared to control (Figure 1 C, Online Table II). 16 
Diaphragm thickness was moderately correlated to Pimax (R=0.44, p=5.0E-3), the latter also correlated 17 
to vital capacity (r=0.47; p=3.0E-3) (Figure 1 D-E). Spirometry showed vital capacity, absolute FEV1, 18 
and transfer coefficient were lower in CHF, but FEV1/VC, residual volume und resistance were 19 
comparable between groups (Table 1). No patient had a FEV1/VC <70% excluding obstructive lung 20 
disease. 21 
 22 
Diaphragm sampling  23 
No serious adverse events occurred during baseline or diaphragm sampling in either group. The time 24 
from intubation to sampling of the diaphragm probes was comparable between both groups (CHF 69 25 
min (95%-CI 53; 85) vs control 64 min (95%-CI 55; 74), p=0.576), which suggests any differences in 26 





Fiber remodeling 1 
Fiber remodeling involving isoform shift and atrophy are suggested to underpin diaphragm weakness in 2 
CHF. We confirmed a fiber-type shift and atrophy in CHF compared to controls: a fast type II to slow 3 
type I was observed (p=0.047) alongside atrophy in both type I and type II fibers with lower cross 4 
sectional areas of 35% and 51% respectively (Figure 2 A-D). The ubiquitin-proteasome system (UPS) 5 
is the major proteolytic pathway responsible for protein degradation, which is rate-limited in wasting 6 
conditions by upregulation of muscle-specific E3 ligases that include MuRF1 and MAFbx. MuRF1 7 
protein expression was higher by 46% (p=3.9E-4) (Figure 2 E), whereas MAFbx protein expression was 8 
lower by 35% in CHF vs control (p=2.0E-3) (Figure 2 F). However, we assume a higher overall E3 9 
ligase activity in CHF that is supported by a 54% higher protein ubiquitination at lysine 48 residues, 10 
with proteasome activity elevated by 54% (p=0.026) (Figure 2 G-H). MuRF1 expression was correlated 11 
with protein ubiquitination at lysine residues (Ubi-K48) (R=0.46, p=0.017) and Ubi-K48 correlated with 12 
proteasome activity (R=0.58, p=2.9E-3) supporting the biological pathway of E3 Ligase dependent 13 
proteasome activation. Moreover, MuRF1 protein expression was correlated with clinical parameters 14 
(diaphragm thickness (R=-0.46, p=0.015), VO2peak (R=-0.43, p=0.024), VE/VCO2 (R=0.40, p=0.045)). 15 
These data implicate diaphragm weakness and atrophy in CHF is underpinned by MuRF1-dependent 16 
ubiquitin-proteasome degradation. 17 
 18 
Oxidative stress  19 
Increased oxidative stress leads to 1) activation of UPS components to elevate protein degradation and 20 
2) contractile dysfunction by damaging sarcomeric proteins. 21 As NADPH oxidases are a major source 21 
of muscle-derived ROS, we confirmed that protein expression of Nox2 and Nox4 isoforms were 2.8- 22 
(p=4.2E-3) and 10.2-fold (p=1.4E-3) higher in CHF vs controls (Figure 2 I-J). ROS-induced protein 23 
damage was evident in CHF as indicated by a 33% higher carbonylation of myosin heavy chain in CHF 24 
vs controls (p=0.015) (Figure 2 K), supporting higher oxidation of myofibrillar proteins. Nox2 was 25 
correlated to MuRF1 expression (R=0.40, p=0.049) and Ubi-K48 (R=0.67, p<1.0E-4) (Figure 2 L). 26 
Nox2 also correlated with in vivo measures as diaphragm thickness (R=-0.52, p=3.3E-3), VO2peak (R=-27 
0.72, p=1.1E-5) and VE/VCO2 (R=0.56, p=1.5E-3) (Online Table IV). Overall, these data suggest that 28 
NADPH oxidases are likely a major upstream mechanism inducing oxidative stress causing diaphragm 29 
weakness in human CHF 5, at least partially via 1) activating components of the UPS to elevate protein 30 
degradation, leading to muscle atrophy, and 2) inducing contractile dysfunction by damaging sarcomeric 31 
proteins. Those molecular mechanisms are linked to whole-body exercise intolerance. 32 
 33 
Mitochondrial function and morphology  34 
Since mitochondrial dysfunction is known to play a key role in fiber atrophy, and Nox4 interacts with 35 
mitochondria, we next examined the mitochondria. Mitochondria of CHF exhibited a lower citra te 36 
synthase activity per mg mitochondrial protein (Figure 3 A) and were smaller according to a FACS 37 
analysis of all undamaged mitochondria (Figure 3 B). In addition, state 3 and state 4 respiration were 38 
significantly lower across different substrates for complex I, II, III, and IV in CHF patients compared to 39 
controls (Online Table V). Respiratory control index and ADP/O ratio were not different between groups 40 
irrespective of the substrate indicating comparable phosphorylation efficiency. Representative graphs 41 
are shown for palmitoylcarnitine/malate as complex I substrate in Figure 3 C-F. State 3 respiration was 42 
correlated to in vivo measures of ventilatory efficiency (R=-0.58, p=0.012) and diaphragm thickness 43 
(r=0.60, p=6.4E-3) (Figure 3 G-H) and VO2peak (R=0.57, p=0.014). We used electron microscopy to 44 
assess diaphragm mitochondrial morphology in CHF and control samples, which revealed accumulation 45 
of intermyofibrillar and subsarcolemmal mitochondria characterized by variable size, but predominately 46 
small-sized mitochondria in CHF (Figure 3 I-L). 47 
Given that mitochondrial function depends on both intrinsic function and amount, we assessed 48 
mitochondrial content in patients by examining different mitochondrial markers and enzyme activities 49 
of proteins related to the electron transfer chain (ETC). Mitochondrial quantity was higher in CHF vs 50 
controls indicated by a 2.2-fold elevated porin protein expression (Figure 4 A) and 1.3-fold higher citrate 51 
synthase activity in whole muscle homogenates (Figure 4 B). Succinate dehydrogenase activity 52 
remained unchanged (Figure 4 C). However, after normalizing these values for mitochondrial amount 53 
to provide an index of intrinsic mitochondrial function, both ratios for citrate synthase and succinate 54 
dehydrogenase activity were significantly lower in CHF (Figure 4 B-C). In addition, enzymatic 55 
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complex-I activity was reduced by 41% in CHF, which is in line with the reduced complex-I respiration 1 
found in isolated mitochondria (Figure 4 D). The protein expression of uncoupling protein 3 (UCP3) 2 
was higher in CHF compared to controls (p=0.052) (Figure 4 E), whereas protein expression of 3 
uncoupling protein 2 was not detectable in both CHF and controls (data not shown).  4 
To provide further insights into mitochondrial pathology, we examined parameters of fusion and fission. 5 
The protein expression of the fusion parameter Mitofusin-2 (Mfn2) and the fission parameter cytosolic 6 
GTPase dynamin-related protein 1 (Drp1) was 2.3-fold (p=1.4E-3) and 1.6-fold (p=0.041) higher in 7 
CHF than in controls (Figure 4 F-G) suggesting both increased fusion and fission. To assess 8 
mitochondria biogenesis, we investigated the protein expression of PGC1alpha found to be 1.5-fold 9 
higher in CHF (p=0.032). Autophagy/mitophagy was assessed by evaluating the protein expression of 10 
LC3-I/LC3-II and p62. The ratio LC3-I/LC3-II was 1.4-fold higher in CHF (p=9.0E-3) and p62 protein 11 
expression was 2-fold higher in CHF (p=1.4E-3). The combination of a reduced lipidation of LC3 and 12 
accumulation of p62 indicates inhibited autophagy/mitophagy in CHF. 23 13 
Overall, these data reveal that despite increased measures of overall number and content, intrinsic 14 
dysfunction of mitochondria is present in the CHF diaphragm, potentially caused by impaired 15 
mitophagy. 16 
 17 
Calcium homeostasis 18 
The observed mitochondrial alterations closely mirror those reported to occur when Ca2+ overload is 19 
present consequent to “leaky” ryanodine receptor (RyR1). 24 We investigated the binding status of 20 
FKBP12 to RyR1, which when reduced is a proxy for “leaky” RyR1 to indicate altered Ca2+ homeostasis. 21 
Binding of FKBP12 to RyR1 was lower in CHF compared to controls (p=0.050), which indicated Ca2+ 22 
efflux from the sarcoplasmatic reticulum (SR) into the cytosol (Figure 5 A). There was a parallel 23 
significant increase in protein expression of Ca2+ re-uptake proteins in CHF including SERCA-1 and 24 
SERCA-2A (Figure 5 B-C). Elevated Ca2+ levels can also activate Ca2+-dependent proteases such as 25 
calpains to promote fiber atrophy. 25 We therefore measured calpain activity but did not find a significant 26 
difference between groups (Figure 5 D), which suggests that catabolic activity in the diaphragm of 27 
humans with CHF is potentially driven by the UPS. Impaired Ca2+ homeostasis can also limit excitation-28 
contraction coupling to impair diaphragm contractile function and induce weakness. As such, we next 29 
assessed Ca2+-activated single-fiber contractile function in isolated diaphragm type II fibers, which 30 
revealed significantly reduced myofilament Ca2+ sensitivity in CHF vs controls (Figure 5 E-F).  31 





Our data show that CHF patients suffer from a diaphragm myopathy that occurs independent of disuse 3 
or other confounding factors such as ageing, obesity, or hypertension. Specifically, we confirm using in 4 
vivo and in vitro approaches that diaphragm weakness and wasting is present in CHF, which is 5 
underpinned by severe cellular remodeling and molecular alterations that include fiber atrophy, NOX-6 
related oxidative stress, proteasome-linked catabolic activation, mitochondrial dysfunction, and 7 
impaired Ca2+ homeostasis. Clinically, the molecular alterations closely correlate to both whole-body 8 
exercise capacity and respiratory function. Thus our data reveal, for the first time in humans with heart 9 
failure, a novel molecular mechanism and potential therapeutic target for diaphragm weakness that is 10 
centered around a Nox-MuRF1/ubiquitin proteasome-mitochondria-RyR1/Ca2+ dependent signaling 11 
axis.  12 
 13 
Patient population and clinical data 14 
The CHF group comprised patients with exercise capacity reduced to 57% of the age- and sex-specific 15 
predicted norm. CPX was performed in part under inotropic support, which might explain the slightly 16 
higher VO2peak compared to other left ventricular assist device studies. 
26, 27 In the control group, we 17 
included non-CHF patients undergoing elective coronary artery bypass grafting. Clinically, control 18 
patients did not have CHF and presented with normal measures of LV-EF, nt-proBNP and VO2peak. 19 
Moreover, we excluded patients in both groups with comorbidities known to influence the morphology 20 
and function of the diaphragm, in particular recent mechanical ventilation, COPD, severe chronic and/or 21 
acute renal failure. 22 
The magnitude of diaphragm dysfunction in our study was comparable to other studies including those 23 
examining Pimax as a prognostic marker 
3, 4 and including NYHA III/IV patients who have pronounced 24 
diaphragm weakness. 28 The ratio P0.1/Pimax, commonly interpreted as an index for ventilatory drive, was 25 
higher in CHF compared to controls and comparable to published data. 28 This observation is consistent 26 
with rapid shallow breathing commonly found in advanced CHF. Despite this increased workload, we 27 
found reduced diaphragm thickness in CHF, which is an index of atrophy closely associated with 28 
exercise intolerance in CHF. 29 Structural changes in CHF were associated with in vivo respiratory 29 
dysfunction and cellular markers of proteolysis (i.e. MuRF1) and mitochondrial derangements.  30 
 31 
NADPH oxidase as a major mechanism triggering diaphragm weakness  32 
NADPH oxidases have emerged as one major source of ROS in skeletal muscle cells. 21 An increased 33 
NADPH expression has been observed in both acute 9 and chronic animal models of heart failure. 18 34 
Increased Nox2 protein expression in the diaphragm of CHF patients is in line with a former study 35 
examining Nox2 and its downstream mediators. 5 An ~40% increase of ROS induced protein damage 36 
was also evident 5, which is similar to the increased carbonylation of MHC in our study.  37 
ROS, but also cytokines, angiotensin II and sphingomyelinase, are able to activate proteolytic pathways 38 
in skeletal muscle including the UPS. 30 In the diaphragm of CHF, the UPS appeared to be the dominant 39 
proteolytic system since calpain activity was not significantly different between groups. Moreover, 40 
Nox2 and Nox 4 protein expression was correlated to activation of the key atrogene, muscle-specific E3 41 
ligase MuRF1, and protein ubiquitination, thus supporting the biological pathway of MuRF1-dependent 42 
proteasome degradation of proteins. Both Nox2 and the UPS are linked to diaphragm weakness in animal 43 
models 18, 31 and the genetic knock out of the p47(phox)-Nox2 subunit is associated with reduced ROS 44 
production and preservation of diaphragm function. 18 In humans, the correlation of Nox2 and MuRF1 45 
to in vivo measures of diaphragm morphology and function supports the association between increased 46 
ROS/catabolic activity and whole-body symptoms related to exercise intolerance and respiratory 47 
dysfunction. While we saw an increase in MuRF1 expression, MAFbx was lower in CHF than in 48 
controls. This phenomenon has been observed before with unchanged or reduced expression levels in 49 
humans and animals with heart failure and/or after exercise training. 10, 32, 33 However, we assume a 50 
higher overall E3 ligase activity in CHF supported by increased polyubiquitination at lysine 48 residues 51 
and proteasome activity in CHF, with the former one being the typical polyubiquitination signal for 52 
proteasome dependent degradation 34. Reduction of MAFbx, which predominantly leads to degradation 53 
of initiation factor 3 subunit 5 (eIF3-f) and MyoD35, might be a compensation to the increased 54 
proteolysis of structural proteins by MuRF1 since an increase in eIF3-f leads to increased expression of 55 
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structural proteins and causes muscle hypertrophy. 36 Further research is necessary to investigate the 1 
interaction between these two E3 ligases. 2 
Many studies have focused on Nox2, however, the role of Nox4 in skeletal muscle and the diaphragm 3 
of CHF patients is not well defined. While Nox2 is regulated by phosphorylation of p47(phox) or 4 
p67(phox), and activation of Rac1, Nox4 is constitutively active and, therefore, transcriptionally 5 
regulated. 21 We found an astonishing 10.2-fold higher Nox4 protein expression in the diaphragm of 6 
CHF indicating increased Nox4 activity. While Nox2 is a sarcolemmal protein, Nox4 contains a 7 
mitochondria localization sequence in its N-terminal region and is found in muscle mitochondria and 8 
sarcoplasmic reticulum (SR). 21 Therefore, we assessed mitochondrial function and parameters of 9 
calcium handling to provide further mechanistic insight.  10 
 11 
Mitochondrial function and calcium handling 12 
In isolated mitochondria, we found reduced state 3 and state 4 respiration across different substrates for 13 
complex I-IV in CHF. Electron microscopy revealed accumulation of intermyofibrillar and 14 
subsarcolemmal mitochondria in CHF characterized by variable size, but predominately small-sized 15 
mitochondria, which is in line with the results of the FACS analysis of isolated mitochondria. This might 16 
be the consequence of inhibited autophagy/mitophagy with an imbalance between fusion and fission, 17 
which is discussed below. Increased markers of mitochondria quantity (citrate synthase, porin) 18 
supported a higher amount of mitochondria in CHF. The reduced respiratory capacity across all four 19 
electron transport chain (ETC) complexes suggests a defect in complex IV and/or assembly of 20 
supercomplexes. 37 However, this does not exclude impairments in other complex activities. Indeed, we 21 
proved a reduction in enzymatic complex-I- and succinate dehydrogenase activity suggesting that 22 
reduced respiration of complex I and II is not only due to a defect in complex IV but also caused by 23 
complex specific alterations. This may finally lead to a reduced proton gradient across the inner 24 
membrane with reduced capacity for ATP production contributing to impaired muscle function and 25 
exercise capacity. 38 From a clinical point of view, this hypothesis is supported by our correlative 26 
analysis between a reduced state 3 respiration vs ventilatory efficiency and VO2peak derived from whole 27 
body exercise testing. 28 
To elucidate potential reasons for the impaired mitochondrial function in CHF, we evaluated markers 29 
controlling the quality of the mitochondrial network. A higher protein expression of Mfn2 and Drp1 in 30 
CHF indicates increased fusion and fission. Both parameters are sensitive to exercise 39 and the observed 31 
higher expression might be the consequence of a higher ventilatory workload in CHF. The same could 32 
be the case for PGC1alpha known to be very sensitive to exercise. 39 In contrast, the combination of a 33 
reduced lipidation of LC3 and accumulation of p62 indicates inhibition of autophagy/mitophagy in CHF. 34 
23 Blocked mitophagy is associated with a diminished mitochondrial function 40 and protein expression 35 
of ETC enzymes. 39 Therefore, this finding might serve as an explanation for the reduced mitochondrial 36 
function observed in the diaphragm of CHF patients. Further research is necessary to elucidate the 37 
reasons for autophagy inhibition. 38 
Moreover, we found an increased UCP3 expression, which can be the consequence of elevated ROS. 39 
Increased UCP3 is found after acute exercise and is thought to alleviate the proton gradient across the 40 
inner membrane, thereby reducing excessive ROS production but also ATP production by the ETC. 41 41 
In CHF, a similar scenario may occur in response to the increased work of breathing and acute episodes 42 
of dyspnea 7, potentially aggravated by hypoxia. 42 Another hypothesis is Nox4 induced mitochondrial 43 
stress, which is supported by the correlation between Nox4 and UCP3 in our patient cohort. Cardiac-44 
specific Nox4-deletion attenuated mitochondrial dysfunction in response to pressure overload in mice 45 
being associated with reduced ROS production and oxidative damage to mitochondrial proteins. 43 46 
Several mechanisms can account for the cross talk between Nox4, mitochondria and the SR including 47 
oxidation of mitochondrial ETC proteins or oxidation of the RyR within the SR. 21 The latter one causes 48 
a Ca2+ leak from the SR. 24 Mitochondria act as a buffer with the result of Ca2+ overload, which in return 49 
induces mitochondrial dysfunction. 24 Additionally, impaired mitophagy is associated with increased 50 
mitochondrial Ca2+ uptake and a reduced Ca2+ availability for contraction. 40 Such a feedback-loop 51 
between the SR and mitochondria in which SR Ca2+ leak triggers mitochondrial dysfunction has been 52 
described in failing myocytes 24 and in the diaphragm during mechanical ventilation. 44 Against this 53 
background, we examined the binding status of the subunit FKBP12 to RyR1, which if reduced is a 54 
molecular marker of a “leaky” receptor state. Binding of FKBP12 to RyR1 was lower in CHF compared 55 
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to controls suggesting increased Ca2+ efflux from the SR. We also found an increased protein expression 1 
of calcium re-uptake handling proteins in CHF, which likely indicates a compensatory response to 2 
elevated Ca2+ levels by increasing reuptake pumping. Moreover, single-fiber contractile function from 3 
CHF patients was impaired, showing reduced Ca2+ sensitivity. The rightward shift of the pCa2+-force 4 
curve indicates that diaphragm fibers of CHF patients generate a lower force of their maximal for a 5 
given Ca2+ concentration. 14 This suggests that contractile function in the CHF diaphragm is even more 6 
affected at submaximal than at maximal activation, which is clinically relevant as the diaphragm most 7 
often works at submaximal workloads. Overall, our data confirm impaired Ca2+ homeostasis in the 8 
diaphragm of CHF patients, which is caused by leaky RyR1 coupled to reduced myofibrillar sensitivity 9 
and mitochondrial dysfunction. 10 
 11 
Limitations 12 
Our results should be interpreted against the background of the following limitations. First, the control 13 
group was not a healthy comparator since patients had coronary artery disease requiring coronary artery 14 
bypass grafting; however, for reasons of gathering both clinical data and diaphragm biopsy, this was the 15 
most appropriate group in our setting. Second, CHF were slightly younger than controls. We believe 16 
that the difference of 7 years was not clinically meaningful. It even underlines the robustness of our 17 
findings since respiratory function decreases with age. Third, CHF comprised both ischemic and dilated 18 
cardiomyopathy, but number of patients was not sufficient to make meaningful comparisons between 19 
both entities. Fourth, Nox2 and Nox4 subunits are expressed in several other cell types (e.g., 20 
macrophages, endothelium, and smooth muscle cells), which may have made minor contribution to our 21 
muscle homogenate data. Fifth, single fiber measurement could only be done in type II fibers due to 22 
contracted type I fibers. Preserving techniques are well established for those contractile measurements 23 
45, 46; therefore, this phenomenon remains unclear. However, we do not believe that it was a disease 24 
specific problem because it was found in both CHF and control probes. Moreover, we cannot rule out 25 
that a fiber selection bias affected the outcomes of our contractility assays. To minimize this effect, we 26 
randomly selected fibers for the contractile assays and excluded only those exhibiting injury patterns 27 
that are associated with impossible or unreliable single fiber measurement. Sixth, our data are descriptive 28 
and despite correlative evidence, we cannot provide a cause-relationship despite our assumptions being 29 
supported in some instances by genetic knock out models. We were also not able to examine all the 30 
downstream mediators known to be responsible for ROS production by NADPH oxidases due to tissue 31 
limitation. 21 Moreover, we are not able to distinguish between causative and compensatory molecular 32 
events since it is a single time point analysis in humans and correlation analysis does not mean causality. 33 
To elucidate cause and compensation, longitudinal experiments with specific therapies aimed at specific 34 
molecular components would be necessary. However, it is important to recognize that the 35 
pathophysiology of diaphragm dysfunction seen in different animal models (e.g. catabolic activation, 36 
mitochondrial dysfunction, Nox activation) is also present in human specimens. Those results form a 37 
solid base for development and testing of different treatment strategies in CHF to address respiratory 38 
and skeletal muscle dysfunction including MuRF1 inhibition 47, 48, increasing Ca2+ sensitivity 49 or Nox 39 
inhibition. 50 40 
 41 
Conclusions 42 
CHF patients demonstrate a diaphragm myopathy independent of disuse or other confounding factors 43 
such as ageing, obesity, or hypertension. In vivo diaphragm weakness and wasting induced by CHF were 44 
associated with intracellular abnormalities characterized by fiber atrophy, oxidative stress, 45 
mitochondrial dysfunction, impaired Ca2+ homeostasis, elevated proteasome dependent proteolysis, but 46 
inhibited autophagy/mitophagy, which we speculate is regulated via a Nox-MuRF1/ubiquitin 47 
proteasome-mitochondria-RyR1/Ca2+ signaling axis to offer a novel therapeutic molecular target 48 
(Figure 6). 49 




We are grateful to Claire Boulogne and Cynthia Gillet as the present work has benefited from Imagerie‐2 
Gif core facility supported by l’Agence Nationale de la Recherche (ANR-11-EQPX-0029/Morphoscope, 3 
ANR-10-INBS-04/FranceBioImaging; ANR‐11‐IDEX‐0003‐02/ Saclay Plant Sciences). 4 




NM received funding from the Leipzig Heart Institute (HRC060453). TSB received funding from the 2 
Medical Research Council UK (MR/S025472/1) and Heart Research UK (TRP 16/19). 3 





Norman Mangner reports personal fees from Edwards LifeScience, Medtronic, Biotronik, Novartis, 3 
Sanofi Genzyme, Bayer, Pfizer, and AstraZeneca, outside the submitted work. 4 
Jens Garbade has nothing to disclose. 5 
Estelle Heyne has nothing to disclose. 6 
Marloes van den Berg has nothing to disclose. 7 
Ephraim B. Winzer reports personal fees from Boehringer-Ingelheim, CVRx, and Novartis, outside the 8 
submitted work. 9 
Jennifer Hommel has nothing to disclose. 10 
Marcus Sandri has nothing to disclose. 11 
Joanna Jozwiak-Nozdrzykowska has nothing to disclose. 12 
Anna L. Meyer has nothing to disclose. 13 
Sven Lehmann has nothing to disclose. 14 
Clara Schmitz has nothing to disclose. 15 
Edoardo Malfatti has nothing to disclose. 16 
Michael Schwarzer has nothing to disclose. 17 
Coen A. C. Ottenheijm has nothing to disclose. 18 
T. Scott Bowen has nothing to disclose. 19 
Axel Linke reports grants from Novartis, personal fees from Medtronic, Abbott, Edwards Lifesciences, 20 
Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, Boehringer, and other from Picardia, 21 
Transverse Medical, Claret Medical, outside the submitted work. 22 
Volker Adams has nothing to disclose. 23 
  24 
CIRCRES/2020/318060/R3 16 
 
Supplemental Materials 1 
Expanded Materials & Methods 2 
Online Tables I - V 3 
References only in the Supplement 51-61 4 
 5 
  6 
CIRCRES/2020/318060/R3 17 
 
Figure Legend 1 
 2 
Figure 1 – Clinical assessment of respiratory function. Reduced inspiratory (Pimax) and expiratory 3 
function (Pemax) in patients with heart failure (CHF) compared to control patients (A). P0.1 was equal 4 
between groups, but the ratio P0.1/Pimax was higher in CHF indicating increased respiratory drive (B). 5 
Diaphragm thickness was lower in CHF for both right and left hemi-diaphragm (C). Reduced diaphragm 6 
thickness was associated with reduced Pimax (D). Pimax was associated with reduced vital capacity (E). 7 
Number of patients: A-D) control: 21, CHF: 18; E) control: 20, CHF: 17.  8 
All p-values are two-sided and were not corrected for multiple testing.  9 
Continuous variables were tested for normal distribution applying the Shapiro-Wilk-test. 10 
* unpaired Students t-test.  11 
† Mann-Whitney-U-Test. 12 
 13 
Figure 2 – Diaphragm fiber phenotype, ubiquitin-proteasome system, and NADPH oxidase. 14 
Immunostaining of type-1 fibers (brown) in the diaphragm of control (A) and CHF (B). In seven control 15 
and six CHF patients, an average of 288 type-1 and 164 type-2 fibers per patient were analyzed; 16 
statistical comparisons were made between control and CHF for each fiber type regarding distribution 17 
and cross-sectional area (CSA). CHF had a shift towards type-1 fibers (C) with a reduction of CSA in 18 
both type-1 (slow) and type-2 (fast) fibers (D). Protein expression of the muscle-specific E3-ligase 19 
MuRF1 (E) was higher, whereas the protein expression of another E3-ligase MafBx (F) was lower in 20 
CHF vs controls. Protein ubiquitination (G) and proteasome activity (H) were higher in CHF vs controls. 21 
Protein expression of the NADPH oxidase isoforms Nox2 (I) and Nox4 (J) were higher in CHF vs 22 
controls. The amount of carbonylated myosin heavy chain (MHC) was higher in CHF vs controls (J). 23 
Nox2 protein expression was correlated to protein ubiquitination (K).  24 
Number of patients: E) control: 16, CHF: 11; F) control: 19, CHF: 12; G) control: 18, CHF: 12; H) 25 
control: 16, CHF: 9; I) control: 18, CHF: 12; J) control: 15, CHF: 12; K) control: 6, CHF: 6; L) control: 26 
16, CHF: 11.  27 
All p-values are two-sided and were not corrected for multiple testing.  28 
Continuous variables were tested for normal distribution applying the Shapiro-Wilk-test. 29 
* unpaired Students t-test.  30 
† Mann-Whitney-U-Test. 31 
 32 
Figure 3 – Isolated mitochondrial measures. The activity of citrate synthase (relative to mitochondrial 33 
protein content) (A) and mitochondrial size (B) was lower in CHF vs controls. State 3 (C) and state 4 34 
respiration (D) of complex I using palmitoylcarnitine/malate as substrate with significantly lower values 35 
in CHF vs controls. The respiratory control index (RCI, E) and ADP/O ratio (F) were comparable 36 
between both groups. State 3 respiration (glutamate/malate) was associated with exercise capacity (G) 37 
and diaphragm thickness (H). Electron micrograph showing normal mitochondria localized in 38 
correspondence of sarcomeric Z-disk in a control patient (I, J). In CHF, we found intermyofibrillar 39 
mitochondria with small size (K) and prominent accumulation of mitochondria with variable size in 40 
subsarcolemmal areas (L).  41 
Number of patients: A) control: 12, CHF: 9; B) control: 10, CHF: 5; C) control: 11, CHF: 6; D) control: 42 
11, CHF: 6; E) control: 11, CHF: 6; F) control: 11, CHF: 6; G) control: 12, CHF: 6; H) control: 12, 43 
CHF: 6; I-L) control: 5, CHF: 5. 44 
All p-values are two-sided and were not corrected for multiple testing.  45 
Continuous variables were tested for normal distribution applying the Shapiro-Wilk-test. 46 
* unpaired Students t-test.  47 
† Mann-Whitney-U-Test. 48 
 49 
Figure 4 – Mitochondrial protein, enzyme activities and morphology. Protein expression of porin 50 
(A) and citrate synthase activity (B, left side) was higher in CHF vs controls indicating increased 51 
mitochondrial content. Citrate synthase activity relative to porin expression (B, right side) and succinate 52 
dehydrogenase activity relative to porin expression (C, right side) were lower in CHF vs controls, 53 
whereas absolute succinate dehydrogenase activity was not different (C, left side). Enzymatic complex 54 
I activity was significantly lower in CHF vs controls (D). Protein expression of uncoupling protein 3 55 
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(UCP3) was higher in CHF (E). Higher protein expression of Mfn2 (F) and Drp1 (G) in CHF vs controls. 1 
Protein expression of PGC1alpha was higher in CHF vs controls (H). Both LC3-I/LC3-II ratio (I) and 2 
p62 protein expression (J) were higher in CHF vs controls.  3 
Number of patients: A) control: 16, CHF: 12; B) control: 17/15, CHF: 9; C) control: 16, CHF: 12; D) 4 
control: 14, CHF: 9; E) control: 17, CHF: 12; F) control: 17, CHF: 11; G) control: 15, CHF: 12; H) 5 
control: 19, CHF: 12; I) control: 16, CHF: 12; J) control: 17, CHF: 11. 6 
All p-values are two-sided and were not corrected for multiple testing.  7 
Continuous variables were tested for normal distribution applying the Shapiro-Wilk-test. 8 
* unpaired Students t-test.  9 
† Mann-Whitney-U-Test. 10 
 11 
Figure 5 – Markers of calcium homeostasis in the diaphragm. Immunoprecipitation for RyR1 12 
showing reduced binding of FKBP12 in CHF vs controls (A). Protein expression of SERCA-1 (B) and 13 
SERCA-2A (C) were higher in CHF vs controls. Calpain activity was not different between CHF and 14 
controls (D). Calcium sensitivity was lower in CHF when measured in isolated single type II fibers (E-15 
F).  16 
Number of patients: A) control: 4, CHF: 4; B) control: 17, CHF: 13; C) control: 18, CHF: 11; D) control: 17 
14, CHF: 9; E-F) control: 12, CHF: 9 (an average of 12 fibers per subject were evaluated).  18 
All p-values are two-sided and were not corrected for multiple testing.  19 
Continuous variables were tested for normal distribution applying the Shapiro-Wilk-test. 20 
* unpaired Students t-test.  21 
† Mann-Whitney-U-Test. 22 
 23 
 24 
Figure 6 – Proposed mechanisms in Heart Failure associated Diaphragm Dysfunction (HFaDD) 25 
based on the presented data. Sarcolemmal-bound Nox2 and sarcoplasmic reticulum (SR) and 26 
mitochondrial associated Nox4 are two major sources of reactive oxygen species (ROS) that drive 27 
diaphragm weakness via promoting fiber atrophy and contractile dysfunction. ROS-mediated activation 28 
of the ubiquitin-proteasome system (UPS) to induce atrophy in a MuRF1-dependent manner, while also 29 
inducing protein oxidation to impair key contractile proteins such as myosin heavy chain. Inhibited 30 
mitophagy, ROS-mediated mitochondrial dysfunction and damage of the SR to induce calcium efflux 31 
via “leaky” ryanodine receptors, which proceeds as a vicious circle to exacerbate mitochondrial and 32 
contractile dysfunction. 33 
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Novelty and Significance 1 
 2 
What Is Known? 3 
 The diaphragm is the main inspiratory muscle responsible for normal ventilation. 4 
 In chronic heart failure (CHF), diaphragm weakness is associated with a worse prognosis; 5 
however, we have limited understanding of the basic molecular mechanisms with most of the 6 
data derived from animal studies. 7 
 8 
What New Information Does This Article Contribute? 9 
 Clinical, functional (in vivo/in vitro), histological/ultrastructural and molecular alterations of 10 
diaphragm biopsies from CHF patients receiving a left ventricular assist device were compared 11 
to biopsies of patients without CHF undergoing elective coronary bypass grafting (control).  12 
 NADPH oxidase isoform Nox2 and Nox4 expression was increased in CHF accompanied by 13 
catabolic activation and reduced cross-sectional area of type-I and type-II fibers, whereas 14 
mitochondria exhibited functional and ultrastructural abnormalities characterized by inhibited 15 
autophagy/mitophagy. 16 
 Molecular measures were associated with a clinically evident respiratory muscle dysfunction 17 
and reduced whole body exercise capacity in CHF.  18 
 19 
Diaphragm weakness in CHF is both responsible for aggravated symptoms and is associated with a 20 
worse prognosis. The molecular mechanisms in humans with CHF are poorly understood and, therefore, 21 
specific treatment options are lacking.  Our data derived from in vivo measures and molecular analyses 22 
of diaphragm biopsies revealed that CHF patients suffers from a diaphragm myopathy that occurs 23 
independent of disuse or other confounding factors such as ageing, obesity, or hypertension. 24 
Specifically, we confirm that severe cellular remodeling and molecular alterations including fiber 25 
atrophy, oxidative stress, proteasome-linked catabolic activation, mitochondrial dysfunction, and 26 
impaired Ca2+ homeostasis underpin diaphragm weakness and wasting in CHF. Clinically, the molecular 27 
alterations closely correlate to both whole-body exercise capacity and respiratory function. Thus, our 28 
data reveal, for the first time in humans with heart failure, a molecular mechanism and potential 29 
therapeutic target for diaphragm weakness that is centered around a cross-talk of NADPH oxidase 30 
derived oxidative stress, catabolic activation via the ubiquitin-proteasome system, quantitative and 31 
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